NCT06487078View on ClinicalTrials.gov

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

NARecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions
ALK+ Non-Small-Cell Lung Carcinoma
Interventions
DRUG

Lorlatinib

ALK-positive NSCL treatment

Trial Locations (1)

51056

RECRUITING

Institut Godinot, Reims

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06487078 - Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context | Biotech Hunter | Biotech Hunter